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Abstract
Human endocrine tumors often express the somatostatin receptors SSTR 1–5 with different
intensity. It has been widely investigated their distribution in pituitary adenomas, brain tumors,
adrenal tumors and neuroendocrine tumors in gastrointestinal tract (NET). Some of studies also
concern the expression of SSTRs in thyroid tumors but they are mainly limited to parafollicular C
cells – derived medullary thyroid carcinomas (MTC). Results of SSTR 1–5 detection in other
thyroid pathologies like follicular adenomas and papillary cancers are still scarce and often
controversial, depending of investigation method used. The aim of this study was to report the
presence of all the 5 subtypes of SSTR (including 2A and 2B SSTR isoforms) in some surgically
treated human thyroid tumors by means of immunohistochemistry and real-time PCR method and
to correlate the results obtained with both techniques. SSTR 1 protein was expressed in 88.8% of
investigated cases, SSTR 2A and 2B both in 44.4%, SSTR 3 in 55.5%, SSTR 4 in 11.2% and SSTR 5
in 33.3%. SSTR 1 is the dominant form in the thyroid gland tumor and hyperplasia. We found
positive confirmation of both methods in 88.8% for SSTR 1, 2A, 3 subtypes, in 22.2% for SSTR 4
and in 100% for SSTR 5. It suggests that somatostatin multiligand analogs or selective SSTR 1
agonists may be used in thyroid tumors treatment.
Background
Somatostatin (SST) as well as its synthetic analogs are
engaged in regulation of hormones secretion in different
ways and this action depends on specific receptors expres-
sion which are present on the target cells. Five subtypes of
the SST receptor have been identified so far, i.e. SSTR 1–5.
SSTR 2 is present in two splicing variants (2A and 2B)
[1,2]. All of them belong to a group of 7 transmembrane
domains linked with the G protein [3] and are encoded by
5 genes which are present on separate chromosomes [4,5].
In the cell the SST receptors can be found on the cell mem-
brane or in the cytoplasm. Particular SSTR subtypes can
occur alone or be grouped together in the same cell. SSTR
are present both in normal and in tumor tissues which
enables their response to applied SST analogs [6]. Human
endocrine tumors often express the somatostatin recep-
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tors SSTR 1–5 with different intensity. It has been widely
investigated their distribution in pituitary adenomas,
brain tumors, adrenal tumors and neuroendocrine
tumors in gastrointestinal tract (NET). Some of studies
also concern the expression of SSTRs in thyroid tumors
but they are mainly limited to parafollicular C cells –
derived medullary thyroid carcinomas (MTC) [7-9].
Results of SSTR 1–5 detection in other thyroid pathologies
like follicular adenomas and papillary cancers are still
scarce and often controversial [10-13] depending of inves-
tigation method used (see Table 1).
Majority of studies applied the molecular biology meth-
ods of SSTRs investigation. These include the reverse –
transcriptase PCR (RT-PCR), in situ hybridization (ISH),
real-time PCR (RT-PCR) and Northern-blotting which are
searching the expression of receptors at the level of
mRNA. Apart from that, molecular biology methods are
often burdened with some limitations like the necessity to
use frozen tissue from surgical samples, very expensive
reagents to perform the molecular reaction and some-
times gives false positive results. SSTRs investigation by
immunohistochemical methods (IHC) is searching the
expression of receptors at the level of receptor protein and
gives us insight into receptor's cellular localization. The
immunohistochemical technique can be also performed
on paraffin embedded tissue specimens obtained from
surgically removed tumors which are routinely used for
histopathological examinations and seems to be the best
ex vivo in vitro method in detecting cellular distribution of
SST receptors [14]. In our previous study we proved high
efficacy of immunohistochemical detection of SSTR
expression in human pituitary adenomas, adrenal gland
tumors and neuroendocrine tumors using antibodies spe-
cific for a given receptor subtype [15-17]. This method
should be considered supplementary or even equally
effective as methods of molecular biology or in vivo recep-
tor radiodiagnostic imaging.
The aim of this study was to report the presence of all the
5 subtypes of SSTR (including 2A and 2B SSTR isoforms)
in some surgically treated human thyroid tumors by
means of immunohistochemistry and real-time PCR
method and to correlate the results obtained with both
techniques.
Methods
In this study 9 samples obtained during surgically treated
thyroid diseases were assessed. The material was obtained
from 7 women and 2 men aged between 32 and 79 years
(mean age 56 years). Four samples (nr 1–4) were diag-
nosed histopathologically as thyroid cancers, five samples
(nr 6–10) concerned benign lesions of the thyroid gland
(Table 2). This project received the approval of the Ethics
Committee of Medical University of Łódź nr: RNN/97/
06/KE dated 16.05.2006.
Immunohistochemistry
Bouin's fixed, dehydrated and paraffin embedded 8-μm
sections were immunostained using commercially availa-
ble rabbit polyclonal antisera raised against carboxyl-ter-
minal fragments of specific human somatostatin receptor
subtypes (GRAMSCH Laboratories, Schwabhausen, Ger-
many): SSTR 1 (named SS-840 antibody, corresponding to
amino acid sequence 377–391 of the receptor's peptide
chain), SSTR 2A (SS-800, specific for 355–369 sequence),
Table 1: Expression of somatostatin receptors subtypes in some thyroid lesions – the previous studies
Lesion type SSTR detected Material Methods Authors
Follicular carcinoma SSTR 1, 2A, 2B, 4, 5 -100%, SSTR 
3-negative.
Formalin fixed paraffin embedded 
sections.
IHC [12]
SSTR 1, 3 -moderate, SSTR 2-
faint, SSTR 5-strong, SSTR 4-
negative.
Thyroid cancer cell line 
monolayer and xenograft (MRO-
87, WRO-82).
Semiquantitative RT-PCR with 
ethidium bromide.
[10]
Papillary carcinoma SSTR 1, 2B, 3, 4 -83%; SSTR 2A-
66%, SSTR 5–100%.
Formalin fixed paraffin embedded 
sections.
IHC [12]
SSTR 1, 3, 5 -moderate, SSTR 2 – 
faintly detectable, SSTR 4 – 
negative.
Thyroid cancer cell line 
monolayer and xenograft (NPA 
87, KAT-10).
Semiquantitative RT-PCR with 
ethidium bromide.
[10]
SSTR 2 -87%. Paraffin embedded sections. IHC [13]
SSTR 2–68%, SSTR 5–50%, SSTR3 
-31%, SSTR 1, 4 – not found.
Frozen tissue. RT-PCR [13]
SSTR 1, 3, 4, 5-more than twice 
the background, SSTR 2 -no 
signal.
Frozen biopsied tumor tissue. Northern blot analysis. [21]
Multinodular goiter (MNG) SSTR 2A, 3, 4 -82%, SSTR 2B, 5–
94%, SSTR 1–88%.
Formalin fixed paraffin embedded 
sections.
IHC [12]Thyroid Research 2009, 2:1 http://www.thyroidresearchjournal.com/content/2/1/1
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SSTR 2B (SS-860, specific for 342–356 sequence), SSTR 3
(SS-850, specific for 381–395 sequence), SSTR 4 (SS-880,
specific for 374–388 sequence) and SSTR 5 (SS-890, spe-
cific for 350–364 sequence). The immunohistochemical
procedures were performed as previously described [18].
The working dilution of antibodies was 1: 1000 (diluted in
0.05 M TRIS buffer, pH 7.6 containing 2% goat serum).
Following overnight incubation in 4°C in humidified
chamber with primary antibodies, the cells were treated
with anti-rabbit IgG biotinylated goat antibody (1:800,
DAKO, Denmark) and streptavidin complex (Strept ABC/
HRP, DAKO, Denmark). The immunoreaction was visual-
ized with 3,3'-diaminobenzidine (DAB, DAKO, Denmark)
solution. For negative controls the primary antibody was
omitted and the normal goat serum was used.
The immunoreactive intensity for specific receptor pro-
teins was scored semiquantitatively using a descriptive
scale as follows: strong staining (+++), moderate staining
(++), weak staining (+) and pale staining (+/-). Subcellu-
lar distribution pattern of SSTR subtypes – membranous
or cytoplasmic was also determined.
Real-Time PCR
Total RNA was isolated from 1 g of frozen tissue using
Magna Pure Compact RNA Isolation Kit Cat. No 04 802
993 001 (Roche Molecular Biochemicals) from nine
patients. Total RNA was DNase treated using DNase I
(RNase free) reagent (Ambion Cat. no AM2222). First-
strand cDNAs were synthesized from equal amounts of
total RNA (0,5 μg/reaction) using oligo(dT) and iScript
cDNA Synthesis Kit (Bio-Rad1Cat. No70-8890) according
to the manufacturer's instruction. All primers were pur-
chased in Oligo PAN Warszawa (Table 3) [19,20]. RT-PCR
was performed using pairs of primers in reaction amplify-
ing across a gradient of annealing temperatures to identify
optimal reaction conditions for Real-Time PCR. Real –
Time PCR was performed using an iCycler iQ System (Bio-
Rad Cat No 170-8701, 170-9750). The rate of accumula-
tion of amplified DNA was measured by continuous mon-
Table 2: Expression of somatostatin receptor subtypes in some thyroid gland diseases determined by IHC
No No of patient Histopathological 
determination
SSTR – 1 SSTR – 2A SSTR – 2B SSTR – 3 SSTR – 4 SSTR – 5
P-1. 338542
F-56 years old
Papillary 
carcinoma
+++ mem, part. 
cytopl
+++ mem, part. 
cytopl
+ mem, pale 
cytopl
+/++
cytopl
negative
+ single cells
++ cytopl
P-2. 333508
F-37 years old
Papillary 
carcinoma
+++
cytopl
++
mem/cytopl
++/+++
cytopl
++/+++
cytopl
-/+++
cytopl !!!
-/+++
cytopl
P-3. 334708
F-79 years old
Poorly 
differentiated 
carcinoma
++
mem/cytopl
+
mem/cytopl
+
mem/cytopl
++
cytopl
negative +/-/+
cytopl
P-4. 335385
M-69 years old
Poorly 
differentiated 
carcinoma
+++
mem/cytopl
+/-; +
cytopl
+/- negative +/-/++
cytopl
P-6. 332314
F-45 years old
Lymphatic goiter negative negative negative negative negative +++
cytopl (in the 
single follic. 
struct.)
P-7. 332142
F-32 years old
Nodular 
hyperplasia of 
thyroid gland
++
cytopl
+
cytopl
++/+++
cytopl
+++
cytopl
negative +++
cytopl
P-8. 332567
M-73 years old
Colloido-nodular 
goiter. Follicular 
adenoma
++/+++
cytopl
++
cytopl
+
cytopl
++/+++
cytopl
negative +/++
cytopl
P-9. 332131
F-67 years old
Thyroid goiter 
with signs of focal 
hyperactivity
++
cytopl
+/-
cytopl
++
cytopl
+
cytopl
negative +
cytopl
P-10. 332205
F-44 years old
Nodular 
hyperplasia of 
thyroid gland
+++
cytopl
++
cytopl
++
cytopl
+++
cytopl
negative +
cytoplThyroid Research 2009, 2:1 http://www.thyroidresearchjournal.com/content/2/1/1
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itoring of SYBR Green I fluorescence. Melt Curve of the
reaction products were in each experiment generated.
Specifically, quantitative real-time PCR on the iCycler iQ
was performed in triplicate on 1 μl of template cDNA per
25  μl reaction. iQ supermix reactions consisted of iQ
SYBR Green Supermix (Bio-Rad1Cat. No70-8882) at a
final concentration 1×, 10 nM fluorescein calibration dye,
SYBR Green I, 500 nM of each primer. Reactions were
amplified in a 96-well thin-wall PCR plate (Bio-Rad Cat.
No 223-9441) using the following PCR parameters: 95°C
for 3 min followed by 50 cycles of 95°C for 10 sec, 60°C
for 30 sec, and 72°C for 30 sec. Melt-curve analysis was
performed immediately following amplification by
increasing the temperature in 0,4°C increments starting at
60°C for 85 cycles of 10 sec each. The presence of a single
PCR product was verified by the presence of a single melt-
ing temperature peak.
Real-time RT-PCR reactions for detection of the endog-
enous control gene (HPRT) were always run in parallel in
each experimental run as a reference for accuracy of sam-
ple dilution.
For each experiment the 3-point standard curve was per-
formed with commercial control RNA [Apllied Biosys-
tems Control Total RNA Human 4307281 (100 μl conc.
50 ng/μl) – dilution 1×, 10× and 100×)].
Results
Immunohistochemistry
Immunoreactivity of investigated thyroid tissues was esti-
mate in pathologically altered cells of thyroid cancers and
benign lesions of the thyroid gland. The area of normal sur-
rounding tissue was immunonegative in all investigated
cases. Multiple SSTR subtypes were found to coexist in each
case of investigated tissue (Table 2). Most of the specimens
showed mixed distribution pattern of the receptors – cyto-
plasmic and membranous. Strong and moderate staining
of SSTR 1 which was distributed both in the cytoplasm and
the membranes or only in the cytoplasm was shown in 8
(88,8%) specimens (Fig. 1),(Fig. 2). SSTR 2A was also char-
acterized by mixed distribution – cytoplasmic and mem-
branous. Strong and moderate staining was demonstrated
in 4 cases (44,4%) and in the remaining 4 cases (44,4%)
distribution of this SSTR subtype was fluctuated from weak
to pale. In 4 specimens (44,4%) strong to moderate stain-
ing of SSTR 2B was observed with both membranous dis-
tribution and in the area of the cell cytoplasm. In the other
4 cases the staining intensity was weak or pale. Staining for
SSTR 3 was characterized by cytoplasmic distribution with
various intensity. In 5 (55,5%) out of 9 examined speci-
mens SSTR 3 was found with strong or moderate intensity
in the cell cytoplasm and the remaining 3 cases (33,3%)
showed weak to pale intensity of staining (Fig. 3). There
was no immunostaining of the SSTR 1–3 subtypes in
patient nr 6 with lymphatic goiter. In this case the immu-
noreactivity of SSTR 1, 2A, 2B and 3 was negative in the thy-
roid follicular epithelium but pale to strong staining was
observed in the lymphatic follicles. No presence of SSTR 4
was found in the 8 (88,8%) of investigated cases with
exception of 1 (11,2%) specimen showing cytoplasmic dis-
tribution of this receptor subtype fluctuating from pale to
strong (patient nr 2) (Fig. 4). Similarly to SSTR 3, SSTR 5
was also characterized by exclusively cytoplasmic distribu-
tion with strong and moderate intensity in 3 samples
(33,3%). Another 5 (55,5%) cases demonstrated pale to
moderate staining. In 1 (11,2%) specimen the intensity of
staining was from pale to strong (patient nr 2).
Table 3: Primers sequences applied for quantitative Real-Time PCR
Name Sequence Size of PCR product, bp GenBank accession no.
SSTR 2A (forward)
SSTR 2A (reverse)
5'ATGCCAAGATGAAGACCATCAC 3'
5'TGAACTGATTGATGCCATCCA 3'
171 [19] NM 001050
SSTR 3 (forward)
SSTR 3 (reverse)
5'CTGGGTAACTCGCTTGGTCATCTA 3'
5'AGCGCCAGGTTGAGGATGTA 3'
86 [19] NM 001051
SSTR 1 (forward)
SSTR 1 (reverse)
5'TATCTGCCTGTGCTACGTGC 3'
5'GATGACCGACAGCTGACTCA 3'
217 [20] NM 001049
SSTR 4 (forward)
SSTR 4 (reverse)
5'ATCTTCGCAGACACCAGACC 3'
5'ATCAAGGCTGGTCACGACGA 3'
321 [19] NM 001052
SSTR 5 (forward)
SSTR 5 (reverse)
5'GTGACAACAGGACGCTGGT 3'
5'TGGTGACGGTCTTCATCTTG 3'
156 [20] NM 001053
HPRT (forward)
HPRT (reverse)
5'TGCTTTCCTTGGTCAGGCAGTAT 3'
5'TCAAATCCAACAAAGTCTGGCTTATATC3'
109 [19] NM 000194Thyroid Research 2009, 2:1 http://www.thyroidresearchjournal.com/content/2/1/1
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Real-Time PCR
We consolidated result for endogenous control gene of
hypoxanthine-guanine phosphoribosyltransferase (HPRT)
as negative (score: 0,0) and according to this all remaining
mRNAs were calculated relative to the amount of HPRT and
given in arbitrary units. The diagram presented below show
the mean results of 3 experiments for each primer (Fig. 5).
SSTR 1 mRNA was expressed in all isolated tissues with dif-
ferent intensity. In 7 from 9 cases (77,7%) it is correlated
with immunohistochemical investigation of SSTR 1 where
intensity of staining was from moderate to strong. In 1
patient (nr 4) SSTR 1 mRNA was only slightly elevated
while expression of SSTR 1 protein in IHC was strong. The
inverse situation we observed in patient nr 6 where SSTR 1
mRNA was elevated while protein expression was negative.
SSTR 2A mRNA was elevated in 6 patients (66,6%) thus a
good correlation of RT-PCR and IHC results was observed
in patients: 1,2,7,8,9,10. Patient nr 3 with poorly differen-
Immunostaining of SSTR 1 in papillary carcinoma, patient nr 2  (333508) (× 200) Figure 1
Immunostaining of SSTR 1 in papillary carcinoma, 
patient nr 2 (333508) (× 200). Strong intensity of staining 
distributed in the cytoplasm.
Immunostaining of SSTR 1 in poorly differentiated carcinoma,  patient nr 3 (334708) (× 200) Figure 2
Immunostaining of SSTR 1 in poorly differentiated 
carcinoma, patient nr 3 (334708) (× 200). Moderate 
staining with both cytoplasmic and membranous distribution.
Weak immunostaining of SSTR 3 in non-malignant goiter,  patient nr 9 (332131) (× 200) Figure 3
Weak immunostaining of SSTR 3 in non-malignant 
goiter, patient nr 9 (332131) (× 200). Cytoplasmic distri-
bution with weak intensity of staining.
Immunostaining of SSTR 4 in papillary carcinoma, patient nr 2  (333508) (× 400) Figure 4
Immunostaining of SSTR 4 in papillary carcinoma, 
patient nr 2 (333508) (× 400). Cytoplasmic distribution of 
this receptor subtype fluctuates from pale to strong.Thyroid Research 2009, 2:1 http://www.thyroidresearchjournal.com/content/2/1/1
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tiated carcinoma had expression of SSTR 2A protein with
weak intensity (Fig. 6) and this result was also in agreement
with low score of RT-PCR. It gives summary 77,7% of good
correlation. The different situation appeared in patients nr
4 and 6 (22,2%) were pale or negative immunostaining of
SSTR 2A and 2B was not correlated with high score of SSTR
2A gene expression. The same results in these patients (nr
4, 6) (22,2%) we observed in case of SSTR 3 subtype. Pale
or negative immunohistochemical score was not correlated
with high score of SSTR 3 gene expression. Immunostain-
ing of SSTR 3 was in agreement with RT-PCR method in 7
cases (patients: 1,2,3,7,8,9,10) (77,7%) were strong and
moderate staining corroborates with the presence of high
and elevated score of SSTR 3 mRNA. Only two negative
results of SSTR 4 mRNA estimation (22,2%) were good cor-
related with negative immunohistochemical staining
(patients: 3,4). No immunostaining of SSTR 4 was
observed in patients: 1,6,7,8,9,10 but a slightly or elevated
gene expression was observed in them. In 1 sample (patient
nr 2) exceptional fluctuated distribution of SSTR 4 from
pale to strong was correlated with faintly detectable gene
expression. In all 9 samples (100%) high or low score of
SSTR 5 mRNA expression was well correlated with strong to
pale IHC staining.
Discussion
We demonstrated in our investigation that somatostatin
subtype receptors are widely distributed in human thyroid
diseases with different intensity and cellular localization.
It is consists with earlier reports of England et al.[12] who
find positive immunostaining in number of investigated
tissues in relation to type of thyroid pathology. The cited
authors have found that for 6 investigated cases with pap-
illary carcinomas 5 patients had SSTR 1, 2B, 3 and 4 recep-
tor subtype (83%). In all of them SSTR 5 was observed
(100%) and SSTR 2A was expressed in 4 cases (66%). In
multinodular goiters SSTR 2A, 3 and 4 were expressed in
82% cases, SSTR 2B, 5 in 94% and SSTR 1 was expressed
in 88%. In our IHC study in 88,8% of investigated cases
we find SSTR 1 with strong and moderate immunostain-
ing. In contrast, the expression of SSTR 2A and 2B was
found in 44,4%, SSTR 3 in 55,5%, SSTR 4 in 11,2% and
SSTR 5 in 33,3% of cases. Our results are conflicting with
England et al. in the scope of SSTR 4, where we did not
detect SSTR 4 at the protein level in multinodular goiter
(MNG) cases using the immunohistochemical method.
Maybe other type of specific anti-SSTR 4 antibody was
used in both experiences. Thus our results show that SSTR
1 but not other subtypes is the dominant form in the thy-
roid gland tumors and hyperplasias. The molecular biol-
ogy method results prove the predominance of SSTR 1, 2A
and 3 mRNAs. These data suggest that despite of the con-
ventional somatostatin analogs: octreotide and lanre-
otide, multiligand analogs such as SOM 230 or KE 108 or
selective ligands of SSTR 1 may be useful in thyroid
tumors treatment. Our material is to scarce to estimate the
Somatostatin 1, 2A, 3, 4, 5 receptor subtypes gene expression determined by RT-PCR method Figure 5
Somatostatin 1, 2A, 3, 4, 5 receptor subtypes gene expression determined by RT-PCR method. mRNAs for SST 
receptors subtypes were calculated relative to the amount of HPRT control gene and given in arbitrary units. Std-standard 
1,2,3 of endogenous control gene. Unkn – expression of SSTR mRNA in patients (1–4), (6–10). sstr1, 2, 3, 4, 5 = SSTR 1, 2A, 
3, 4, 5 mRNA.Thyroid Research 2009, 2:1 http://www.thyroidresearchjournal.com/content/2/1/1
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possible differences between benign and malignant thy-
roid lesions, however, poorly differentiated cancers char-
acterize by low expression of SSTR 2 (Fig. 6). It is worth
interesting that in cancer tissue the expression of SSTR 1,
SSTR 2A, SSTR 2B may be membrane or cytoplasmic (Fig.
1), (Fig. 2), (Fig 6), whereas in non-cancer tissue the
expression of these receptors was only cytoplasmatic (Fig.
7). This observation may suggest the higher responsive-
ness of SSTR in highly differentiated malignant tumors
than in benign lesions. In the Druckenthaner's experi-
ences [13] SSTR 2 immunohistochemistry was positive in
87% of the samples with thyroid tumors. SSTR 2 mRNA
expression well correlated with immunohistochemical
staining pattern in 13/16 samples (81%). In this study the
SSTR 2 mRNA was the predominantly expressed on thy-
roid tumors (68%), SSTR 5 and SSTR 3 mRNAs were less
predominant (50% and 31% respectively). No SSTR 3 and
SSTR 4 mRNAs was found in any specimens. Also Forssell-
Aronsson's group [21] reported that in surgical specimens
SSTR 1, 3, 4, 5 mRNAs were frequent expressed but SSTR
2 mRNA was not detected. Similar results were observed
earlier by Ain [10] but in the thyroid carcinoma cell lines
not in surgically isolated tissues. Most thyroid cancer cell
line monolayers and xenografts expressed SSTR 3 and
SSTR 5 mRNAs whereas SSTR 2 mRNA was only faintly
detectable. In our experiences we found positive confir-
mation of both methods in 77,7% for SSTR 1, 2A, 3 sub-
types, in 22,2% for SSTR 4 and in 100% for SSTR 5. The
lack of good correlation between receptor protein expres-
sion (positive immunostaining) and receptor gene expres-
sion (negative by RT-PCR and vice versa) in our study
needs explanations by future examinations. Several causes
should be taken into consideration, e.g. the expression of
SSTR mRNA in tissue elements other than thyroid epithe-
lial cells, like vascular endothelia, parafollicular cells and
lymphoid cells which can lead to the false positive results
of RT-PCR examination or the lower sensitivity of IHC
which in turn can produce the false negative results.
Lastly, the expression on the mRNA and protein levels
should not to be always synchronized.
Conclusion
We proved that somatostatin receptor subtypes are fre-
quently expressed in pathologically altered thyrocytes, in
contrast to normal thyroid follicular epithelium. SSTR 1
protein was expressed in 77,7% of investigated cases,
SSTR 2A and 2B both in 44,4%, SSTR 3 in 55,5%, SSTR 4
in 11,2% and SSTR 5 in 33,3%. SSTR 1 is the dominant
form in the thyroid gland tumor and hyperplasia. A good
correlation with SSTR 1 receptor gene expression was
observed in 77,7% of investigated cases. Immunohisto-
chemical estimation of SSTR 2A and 3 was agree with RT-
PCR method in 77,7%, only 22,2% of results of SSTR 4
mRNA estimation were correlated with immunohisto-
chemical staining and SSTR 5 mRNA was good correlated
with IHC staining in 100% tissues. It suggests that soma-
tostatin multiligand analogs or selective SSTR 1 agonists
may represent a further useful approach for the thyroid
tumors treatment. The expression of somatostatin recep-
tor subtypes in thyroid tumors needs father studies con-
cerning greater and more differentiated group of patients.
Immunohistochemical staining of SSTR 2A in poorly differen- tiated carcinoma, patient nr 3 (334708) (× 400) Figure 6
Immunohistochemical staining of SSTR 2A in poorly 
differentiated carcinoma, patient nr 3 (334708) (× 
400). Weak intensity of SSTR 2A protein staining with mixed 
cytoplasmic and membranous distribution.
Pale immunostaining of SSTR 2A in non-malignant goiter,  patient nr 9 (332131) (× 400) Figure 7
Pale immunostaining of SSTR 2A in non-malignant 
goiter, patient nr 9 (332131) (× 400). Pale cytoplasmic 
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Abbreviations
mem: membranous localization; cytopl: cytoplasmatic
localization; strong staining (+++), moderate staining
(++), weak staining (+) and pale staining (+/-); SST: soma-
tostatin; SSTR: somatostatin receptor subtype; RT-PCR:
real time polimerase chain reaction; RT-PCR: reverse –
transcriptase polimerase chain reaction; ISH: in situ
hybridisation; IHC: immunohistochemistry; NET: neu-
roendocrine tumors in gastrointestinal tract; MTC: medul-
lary thyroid carcinoma; MNG: multinodular goiter;
mRNA: messenger ribonucleic acid; HPRT: hypoxanthine-
guanine phosphoribosyltransferase control gene.
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